Hamlet BioPharma Announces the Completion of the Alpha1H Phase II Study in Non-Muscle Invasive Bladder Cancer

LUND, Sweden, Aug. 21, 2025 /PRNewswire/ -- Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, announces the completion of the successful Phase II clinical trial of the company's drug candidate Alpha1H in patients with cancer...